Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

ÁøÇ༺ À§¾ÏÁ¾¿¡¼­ ¸²ÇÁÀý ¹Ì¼ÒÀüÀÌÀÇ ¿¹ÈÄÀû À¯ÀǼº Clinicopathologic Significance of Lymph Node Micrometastasis in Advanced Gastric Carcinoma

´ëÇѺ´¸®ÇÐȸÁö 2000³â 34±Ç 2È£ p.125 ~ 131
±Ç¿µ¹Ì, ³ëÀçÀ±, °­°æÈÆ,
¼Ò¼Ó »ó¼¼Á¤º¸
±Ç¿µ¹Ì ( Kwon Young-Mee ) 
¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼­¿ïÁß¾Óº´¿ø Áø´Üº´¸®Çб³½Ç

³ëÀçÀ± ( Ro Jae Y. ) 
¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼­¿ïÁß¾Óº´¿ø Áø´Üº´¸®Çб³½Ç
°­°æÈÆ ( Kang Gyeong-Hoon ) 
¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼­¿ïÁß¾Óº´¿ø Áø´Üº´¸®Çб³½Ç

Abstract


There have been some controversies on prognostic significance of lymph node (LN) micrometastasis (MM) in advanced gastric carcinomas (AGCs). The present study aimed at 1) determination of prognostic significance of MM, 2) evaluation of the relationship between MM and clinicopathological parameters, and 3) determination of LN group where MMs were frequently found. We studied 70 cases of AGC without LN metastasis on initial examination. The tumors were examined for location, size, depth of invasion, differentiation, histologic type, lymphatic invasion, and c-erbB-2 expression. To evaluate MM, pancytokeratin immunohistochemistry was performed in all LNs from 70 cases of AGCs. Among 2,203 dissected LNs from 70 patients, 37 (1.6%) LNs from 19 (27.1%) patients revealed MM. Micrometastases were seen in only group 1 and 2 LNs: none had group 3 and 4 LN involvement. The gender, age, tumor size, location of tumor, histologic type, differentiation, depth of invasion, lymphatic invasion, and c-erbB-2 expression were not significantly associated with MM status. The survival time of the MM-positive group (mean: 62 months) was significantly shorter than that of the MM-negative group (mean: 72 months) (p=0.046). The findings of this study indicate that the presence of MM in LNs is an important prognostic factor in AGC patients.

Å°¿öµå

Advanced gastric carcinoma;Cytokeratin;Micrometastasis

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS